Insights on the Cell and Gene Therapy Global Market to 2026 - by Therapy Type, Product, Application and Region
February 23, 2022 05:13 ET
|
Research and Markets
Dublin, Feb. 23, 2022 (GLOBE NEWSWIRE) -- The "Global Cell and Gene Therapy Market 2021-2026" report has been added to ResearchAndMarkets.com's offering. The global market for cell and gene...
Global CRISPR Market & Competition Landscape 2021-2028 Featuring Profiles of Integrated DNA Technologies, Intellia Therapeutics, Horizon Discovery Group, and Precision Biosciences Among Others
February 04, 2022 05:38 ET
|
Research and Markets
Dublin, Feb. 04, 2022 (GLOBE NEWSWIRE) -- The "Global CRISPR Market 2021-2028" report has been added to ResearchAndMarkets.com's offering. The global CRISPR market is anticipated to display growth...
Outlook on the Oligonucleotide Synthesis Global Market - Featuring Abbott Diagnostics, Amyris and Bayer Among Others
February 03, 2022 04:38 ET
|
Research and Markets
Dublin, Feb. 03, 2022 (GLOBE NEWSWIRE) -- The "Oligonucleotide Synthesis Markets - Forecasts by Oligo Length, Application, and Product - With Executive and Consultant Guides and including Customized...
Global CRISPR Gene Editing Market Report 2021-2031: Opportunities in Expanding Gene and Cell Therapy Area & CRISPR Gene Editing Scope in Agriculture
January 14, 2022 05:33 ET
|
Research and Markets
Dublin, Jan. 14, 2022 (GLOBE NEWSWIRE) -- The "CRISPR Gene Editing Market - A Global and Regional Analysis: Focus on Product, Application, End User, and Country-Wise Analysis - Analysis and...
Meiogenix Announces $13 Million Series A Financing Round Led by Sofinnova Partners
December 14, 2021 03:00 ET
|
MEIOGENIX
Paris, France, Dec. 14, 2021 (GLOBE NEWSWIRE) -- Meiogenix, an agriculture biotech company using the process of Chromosome Editing to expand genetic diversity in food and agriculture, announced...
Exavir Therapeutics announces preclinical data demonstrating complete elimination of HIV from human cells with LNP-delivered Tat-targeted CRISPR-Cas9
November 10, 2021 07:30 ET
|
Exavir Therapeutics
Early candidate from XVIR-TAT series demonstrated genetic elimination of HIV and robust anti-retroviral activity with CRISPR-Cas9 based excision Exavir lipid nanoparticles (LNPs) with mRNA...
Intellia Therapeutics Presents Preclinical Data Demonstrating Advancements in its Broad Genome Editing Capabilities at the 2021 European Society of Gene & Cell Therapy Annual Congress
October 20, 2021 07:30 ET
|
Intellia Therapeutics, Inc.
First preclinical data demonstrating Intellia’s allogeneic platform creates immune-evading T cells for therapeutic use in future cancer treatmentsDemonstrated lipid nanoparticle-based delivery as a...
Intellia Therapeutics and SparingVision Announce Strategic Collaboration to Develop Novel Ocular Therapies Using CRISPR/Cas9 Technology
October 13, 2021 07:01 ET
|
Intellia Therapeutics, Inc.
Collaboration combines Intellia’s proprietary genome editing technology platform with SparingVision’s significant ophthalmology expertise Intellia will grant SparingVision exclusive rights to its...
Evelyn D’An Joins Cytovia Therapeutics as Chief Financial Officer
October 12, 2021 12:24 ET
|
Cytovia Therapeutics
AVENTURA, Fla., Oct. 12, 2021 (GLOBE NEWSWIRE) -- Cytovia Therapeutics, Inc. (“Cytovia”), a biopharmaceutical company developing allogeneic “off-the-shelf” gene-edited iNK and CAR (Chimeric Antigen...
Nobel Prize Winner Dr. Jennifer A. Doudna to Receive Top Award from the Women in Medicine Legacy Foundation
October 12, 2021 11:10 ET
|
The New York Academy of Medicine
New York, NY, Oct. 12, 2021 (GLOBE NEWSWIRE) -- Jennifer A. Doudna, PhD, who earned the 2020 Nobel Prize in Chemistry for her groundbreaking development of genome-engineering technology, is the 2021...